12/17
04:32 pm
alks
Alkermes (NASDAQ:ALKS) had its "buy (b-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Alkermes (NASDAQ:ALKS) had its "buy (b-)" rating reaffirmed by analysts at
Weiss Ratings.
12/11
04:15 pm
alks
Alkermes (NASDAQ:ALKS) had its "buy (b-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Alkermes (NASDAQ:ALKS) had its "buy (b-)" rating reaffirmed by analysts at
Weiss Ratings.
12/11
11:28 am
alks
Trends and Market Growth Opportunities in the Alcohol Use Disorder Industry, 2025-2032 [Yahoo! Finance]
Low
Report
Trends and Market Growth Opportunities in the Alcohol Use Disorder Industry, 2025-2032 [Yahoo! Finance]
12/5
04:14 pm
alks
Alkermes (NASDAQ:ALKS) was upgraded by analysts at
Weiss Ratings from a "hold (c+)" rating to a "buy (b-)" rating.
Low
Report
Alkermes (NASDAQ:ALKS) was upgraded by analysts at
Weiss Ratings from a "hold (c+)" rating to a "buy (b-)" rating.
11/25
04:00 pm
alks
Alkermes to Participate in Two Upcoming Investor Conferences
Low
Report
Alkermes to Participate in Two Upcoming Investor Conferences
11/22
07:56 am
alks
Alkermes (NASDAQ:ALKS) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
Alkermes (NASDAQ:ALKS) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
11/19
06:42 am
alks
Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc [Yahoo! Finance]
Low
Report
Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc [Yahoo! Finance]
11/19
06:00 am
alks
Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc
Low
Report
Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc
11/19
06:00 am
alks
Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc
Low
Report
Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc
11/19
12:31 am
alks
TD Cowen Asserts Buy Rating as Alkermes plc (ALKS) Delivers Topline Results for Narcolepsy Treatment [Yahoo! Finance]
Low
Report
TD Cowen Asserts Buy Rating as Alkermes plc (ALKS) Delivers Topline Results for Narcolepsy Treatment [Yahoo! Finance]
11/17
08:43 am
alks
Alkermes (NASDAQ:ALKS) had its price target raised by analysts at Truist Financial Corporation from $50.00 to $55.00. They now have a "buy" rating on the stock.
Low
Report
Alkermes (NASDAQ:ALKS) had its price target raised by analysts at Truist Financial Corporation from $50.00 to $55.00. They now have a "buy" rating on the stock.
11/15
07:11 am
alks
Avadel (AVDL) Soars to 10-Year High on Brewing Bidding War [Yahoo! Finance]
Low
Report
Avadel (AVDL) Soars to 10-Year High on Brewing Bidding War [Yahoo! Finance]
11/14
08:10 am
alks
Alkermes Response to Avadel Announcement [Yahoo! Finance]
Low
Report
Alkermes Response to Avadel Announcement [Yahoo! Finance]
11/14
07:51 am
alks
Alkermes Response to Avadel Announcement
Medium
Report
Alkermes Response to Avadel Announcement
11/14
07:45 am
alks
Alkermes Response to Avadel Announcement
Medium
Report
Alkermes Response to Avadel Announcement
11/13
10:48 am
alks
Alkermes (NASDAQ:ALKS) had its price target lowered by analysts at Wells Fargo & Company from $42.00 to $37.00. They now have an "overweight" rating on the stock.
Low
Report
Alkermes (NASDAQ:ALKS) had its price target lowered by analysts at Wells Fargo & Company from $42.00 to $37.00. They now have an "overweight" rating on the stock.
11/13
08:11 am
alks
Alkermes (NASDAQ:ALKS) had its price target lowered by analysts at Deutsche Bank Aktiengesellschaft from $55.00 to $45.00. They now have a "buy" rating on the stock.
Low
Report
Alkermes (NASDAQ:ALKS) had its price target lowered by analysts at Deutsche Bank Aktiengesellschaft from $55.00 to $45.00. They now have a "buy" rating on the stock.
11/12
07:30 am
alks
Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2
Medium
Report
Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2
11/12
07:30 am
alks
Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2
Medium
Report
Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2
11/11
08:09 am
alks
Alkermes (NASDAQ:ALKS) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating and a $50.00 price target on the stock.
Low
Report
Alkermes (NASDAQ:ALKS) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating and a $50.00 price target on the stock.
11/9
01:13 am
alks
Low
Report
11/6
04:28 pm
alks
Alkermes to Participate in Two Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Alkermes to Participate in Two Upcoming Investor Conferences [Yahoo! Finance]
11/6
04:00 pm
alks
Alkermes to Participate in Two Upcoming Investor Conferences
Medium
Report
Alkermes to Participate in Two Upcoming Investor Conferences
11/6
04:00 pm
alks
Alkermes to Participate in Two Upcoming Investor Conferences
Medium
Report
Alkermes to Participate in Two Upcoming Investor Conferences
11/5
09:00 am
alks
FORM 8.1(a) & (b) (Opening Position Disclosure)
Medium
Report
FORM 8.1(a) & (b) (Opening Position Disclosure)